Skip to main content
. 2021 Aug 9;11:700165. doi: 10.3389/fonc.2021.700165

Figure 2.

Figure 2

Network of eligible comparisons (A) without malignant subtypes, (B) with malignant subtypes. The width of the lines is proportional to the number of clinical trials comparing every pair of direct comparison, and the size of each node is proportional to the number of patients with malignant assigned. Chemo, chemotherapy; HL, Hodgkin lymphoma; OSCC, esophageal squamous cell carcinoma; NSCLC, non-squamous non-small-cell lung cancer.